Industry’s rare disease moves pay off

Date February 28, 2017

The pharmaceutical industry’s growing interest in orphan disease shows no sign of diminishing, and for good reason. The increased R&D investment in these indications in recent years has translated into a growing share of overall pharmaceutical sales, a new EvaluatePharma report finds. 

The drivers of this change include the favourable regulatory treatment of orphans, as well as market exclusivity and pricing advantages that make such drugs much more profitable than non-orphans. It is notable that the top 25 non-oncology orphan drugs in 2022 are expected to show a compounded growth of 18% over the next six years, almost three times the wider market average (see table below).

EvaluatePharma’s report, issued today to coincide with Rare Disease Day, suggests that orphan drugs collectively generated sales of $114bn in 2016, accounting for 16.4% of the global non-generic pharmaceutical market. This rises to $209bn by 2022, at which point these products will represent 21.4% of the overall market, a proportion that will have doubled in just over a decade.

If these sellside consensus forecasts are achieved orphan drugs will have shown a sales growth rate averaging 11.1% a year over the next six years – around double that of non-orphans.    

The report uses a definition of orphans that includes drugs first approved in an orphan indication or, where approved in more than one indication, that have more than 25% of their sales in orphan uses. Furthermore, cancer almost always meets the orphan criteria; oncology has different commercial characteristics from orphans in the more classical sense, though it is attractive to pharma for many of the same reasons.

Narrowed down

A narrowed definition, capturing only drugs that address chronic treatments for rare, life-threatening conditions outside oncology suggests that these top 25 orphans will have collective sales of $37.4bn in 2022, or around 3.8% of global pharmaceutical turnover.

Of course this omits blockbusters that have a number of approved uses, most of which are not orphan. The narrower proportion should be watched carefully, as it gives a good indication of the overall sum spent on the very high-priced treatments for conditions such as cystic fibrosis and rare lysosomal diseases.

Top 25 orphan* drugs in 2022 
      Global sales ($m) 
Product  Company  Indication   2016  2022e 
Soliris  Alexion   PNH, aHUS, (gMG)  2,843  5,139 
Orkambi  Vertex   Cystic fibrosis  980  3,634 
Ofev  Boehringer Ingelheim  Idiopathic pulmonary fibrosis  763  1,827 
Advate  Shire  Haemophilila A  1,258  1,740 
HyQvia   Shire  Primary immune deffiociency  258  1,714 
Uptravi  Actelion (J&J)  Pulmonary arterial hypertension  249  1,679 
Spinraza  Biogen  Spinal muscular atrophy  1,648 
Sandostatin LAR Depot  Novartis  Acromegaly  1,646  1,624 
Opsumit  Actelion (J&J)  PAH  843  1,546 
Gammagard   Shire  Primary immune deficiency  882  1,540 
Xyrem  Jazz Pharmaceuticals  Narcolepsy  1,110  1,476 
Emicizumab  Roche  Haemophilia  1,370 
Samsca  Otsuka   Hyponatraemia  451  1,167 
Strensiq  Alexion   Hyperphosphatasia   210  1,114 
Lanadelumab  Shire  Hereditary angioedema  1,094 
Fabrazyme  Sanofi  Fabry disease   746  1,071 
Myozyme  Sanofi  Pompe disease   802  1,050 
Cerezyme  Sanofi  Gaucher disease   828  979 
SAGE-547  Sage Therapeutics  Super refractory status epilepticus/postpartum depression  973 
LentiGlobin  Bluebird Bio  Heamophilia  969 
Epidiolex  GW Pharma   Dravet/Lennox Gastaut syndrome  852 
Kalydeco  Vertex   Cystic fibrosis  703  849 
Pulmozyme  Roche  Cystic fibrosis  695  792 
Vimizim  BioMarin  MPS Type IV A (Morquio A syndrome)  354  778 
Prolastin-C  Grifols  Emphysema  747  747 
Note: *chronic treatments for rare, life-threatening conditions outside oncology. Source:EvaluatePharma. 

There has been little or no pricing pressure in these areas so far, at least while they remain a single-digit percentage of overall pharmaceutical sales. But there is a concern that at some point the market will face pushback from payers, presumably when an untenable proportion of the budget is spent on a small proportion of patients.  

Alexion’s famous ultra-orphan Soliris remains the lead product in this category. Soliris, with sales of $3.7bn, ranks 27th overall in terms of all pharmaceutical products sales. But with the sellside consensus anticipating approval in generalised myasthenia gravis this is expected to rise to $5.1bn in 2022, by which point EvaluatePharma data suggest that it will have become the ninth-largest selling drug overall.

Competitive changes

Comparison with a similar analysis carried out last year highlights a surprising degree of movement between the top orphans (Industry work on rare diseases continues to bear fruit, March 3, 2016). For example, Roche’s Esbriet and Novo Nordisk’s NovoSeven, which both had prominent places in 2020 based on last year’s consensus data, now seem likely to disappear without trace in 2022, probably as a result of competitive changes in their indications.

And in recent months the orphan space has seen the launch of Biogen’s Spinraza for spinal muscular atrophy and Sarepta’s Exondys 51 for Duchenne muscular dystrophy. The former is expected to join the top 10 orphans by 2020, while the latter just makes the top 30. In a first for this space, however, both have seen US payers move to limit their use (Payers threaten a hard-knock life for orphan projects, January 25, 2017).

Orphans, however they are defined, remain one of the brightest spots of pharmaceutical development, and the legislation framing them is widely claimed to have been a great success in public policy terms. However, there is a risk that before long orphans could face the same sort of pricing pressure as is common in non-orphan indications.

The EvaluatePharma Orphan Drug Report 2017 is available by free download.

To contact the writer of this story email Robin Davison at robind@epvantage.com or follow @RobinDavison2 on Twitter

This content is written, edited and published by EP Vantage and is distributed by Evaluate Ltd. All queries regarding the content should be directed to: news@epvantage.com

EP Vantage is a unique, forward-looking, news analysis service tailored to the needs of pharma and finance professionals. EP Vantage focuses on the events that will define the future of companies, products and therapy areas, with detailed financial analysis of events in real-time, including regulatory decisions, product approvals, licensing deals, patent decisions, M&A.

Drawing on Evaluate, an industry-leading database of actual and forecast product sales and financials, EP Vantage gives readers the insight to make value-enhancing decisions.

EP Vantage SM ©2018 EP Vantage Ltd